PharmaVentures

InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early

OXFORD, England, May 18 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by InDex Pharmaceuticals AB to advise and assist in out-licensing its first in class therapeutic, Kappaproct (DIMS 0150), for the treatment of steroid resistant / dependent Inflammatory Bowel Disea...

PharmaTelevision Launches New Premium Content Service

...until 30 September, 2009. Dr Fintan Walton, CEO of pharmaventures - the company behind PharmaTelevision - said, "Tel...e. As well as PTV News, current programmes include pharmaventures Business Review; The Regional Report; The Financia...tures.com ). Notes to Editors: About pharmaventures A leading results driven organisation,...

Pfizer - Wyeth: Good Deal – Bad Deal?

...o obvious bar to any merger going ahead. About pharmaventures PharmaVentures ( www.pharmaventures.com ) assists ...on advisory services to the Life Science industry. pharmaventures is based in Oxford, UK, and employs over 35 people...of clients from start-ups to global corporations. pharmaventures publishes PharmaDeals Review (ISSN 1756-7874 onlin...

Determining Valuations in Challenging Times

...methodologies available, selected case studies and pharmaventures consultants' experience in deal making advisory se... fit within the deal?" More case studies - pharmaventures highlights the issues and pitfalls PharmaVentu...aTelevision." Notes to Editors: About pharmaventures PharmaVentures assists pharmaceutical and biotech...

PharmaVentures Exploits Fastest Growing Media Channel to Launch First Pharmaceutical Business Television Show

... pharmaventures today announces the launch of a brand new internet-based television show//: pharmaventures Business Review. Dr Fintan Walton, CEO, PharmaVentures, says, ‘This s...

PharmaVentures in Biological Technology

Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM

OXFORD, England, April 24 /PRNewswire/ -- PharmaVentures Ltd, announced today that it has been engaged by Merck & Co, Inc. to advise and assist in divesting its world class research centre, the IRBM, located near Rome, Italy. The engagement will utilise PharmaVentures' pharmaceutical trans...

PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group

... pharmaventures Ltd, announced today that it provided the Helsinn ... Oxford, UK (PRWEB) June 24, 2009 -- pharmaventures Ltd, announced today that it provided the Helsinn ...lease?id=259822 . Dr Fintan Walton, CEO, pharmaventures commented, "PharmaVentures are delighted to h...